RLYB · Rallybio Corp
United States · RS rating 77 · As of 2026-11-03
| Price | 15.86 USD |
|---|---|
| 1-day change | +0.6% |
| RS rating (overall / 1M / 3M / 12M) | 77 / 42 / 63 / 97 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 41 / 43 / 50 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +615.8% |
| Sales growth Q/Q | +4.7% |
| Distance from 52-week high | +7.9% |
| Market cap (USD) | $45.0M |